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Hepatitis B prevalence, risk factors, infection 
awareness and disease knowledge among 
inmates: a cross-sectional study in Switzerland’s 
largest pre-trial prison
Background Hepatitis B virus (HBV) is a major health concern in 
prison, but data are scarce in European prisons. This study aims to 
measure the prevalence of HBV infection, risk factors, awareness 
about infection, and HBV knowledge among inmates in Switzer-
land’s largest pre-trial prison.
Methods Serological blood tests (HBsAg, anti-HBs, and anti-HBc) 
and a standardized socio-demographic and sexual health survey 
were offered to consenting prisoners in 2009 and 2011. HBV knowl-
edge was assessed using a standardized questionnaire among partic-
ipants recruited in 2009.
Findings A total of 273 male participants were included in the 
study (116 participants answered the HBV knowledge survey), with 
38.1% originating from Eastern Europe, 28.2% from sub-Saharan 
Africa, 14.3% from North Africa, and 9.5% from Latin America. 
The prevalence of anti-HBc (resolved/chronic infection) was 38.2% 
and the prevalence of HBsAg (chronic infection) was 5.9%; 14% of 
participants had vaccine-acquired immunity (anti-HBs positive/an-
ti-HBc negative). We estimated that 15.5% of people living in Gene-
va having chronic infection go through the Geneva’s prison. Region 
of origin was significantly associated with chronic/resolved HBV in-
fection (P < 0.001): 72.2% of participants from sub-Saharan Afri-
can, 34.6% from Eastern Europe and 13.2% from other regions. In 
terms of chronic infection, 15.6% of participants from sub-Saharan 
Africa were positive for HBsAg, vs 2% of those from other regions 
(P < 0.001). In stratified analyses, region of origin remained signifi-
cantly associated with HBV infection. Among those with chronic 
infection, only 12.5% were aware of their status. A minority of in-
mates knew how HBV could be transmitted.
Conclusions The primary factor associated with HBV infection in 
this study was the geographical region of origin of participants. Giv-
en the high HBV prevalence found in this prison population, a tar-
geted testing and vaccination approach based on prisoners’ region 
of origin would be a cost-effective strategy when resources are lim-
ited. Additionally, identification of at-risk people should not rely on 
sensitive questions nor self-reported history of HBV. An inclusive ap-
proach to global health needs to incorporate prison population, as 
incarcerated people have a disproportionate burden of HBV infec-
tion and because an important proportion of hard-to-reach chronic 
HBV infected people go through the incarceration system.
Electronic supplementary material: 
The online version of this article contains supplementary material.
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Hepatitis B virus (HBV) infection is a significant public health problem in prison settings with a global in-
cidence estimate of 0.8%-3.8% per year [1-3]. Studies in the United States show that up to 3.7% of prison-
ers suffer from chronic hepatitis B. The proportion is higher in European prisons (4.4% in Denmark, 6.5% 
in Belgium) [4]. The prevalence of anti-HBc antibodies (indicating infection at some point in time) in pris-
oners is 20%-25% in the United States with a wider range in Europe (9% in Ireland, 58% in Greece) [4,5].
There is a higher risk of HBV transmission in prison settings due to the lack of knowledge about HBV 
transmission modes [6], frequent and unprotected sexual intercourse, injection drug use (IDU), tattoo-
ing and other forms of skin piercing, and trauma [2,5,7]. The time period following prison release is also 
important in terms of increased risky behaviours (IDU and unsafe sex) [8]. Crofts et al. [9] showed that 
the annual incidence rate of HBV (per 100 person years) between two separate incarcerations was 12.6% 
(10 of 99 individuals seroconverted at subsequent entry). Such findings highlight the potential benefit of 
addressing hepatitis B prevention during imprisonment [9].
Prison settings provide a unique opportunity to implement HBV infection control measures for incar-
cerated individuals, thus reducing transmission within and outside the prison population [5]. Howev-
er, given the epidemiological variability of HBV in European prisons, HBV prevention, and transmission 
control should be tailored to the local carceral context. This study aims to determine the prevalence of 
HBV serological markers, their associated risk factors, infection awareness and knowledge about modes 
of transmission/protection among inmates of the Champ-Dollon prison in Geneva, the largest pre-trial 
detention center in Switzerland.
METHODS
Study population and data extraction
A cross-sectional study was conducted at the Champ-Dollon pre-trial prison, at two distinct time points 
(2009 and 2011). During two varicella outbreaks, we conveniently offered to consenting participants of 
entire affected prison units a blood test and structured socio-demographic survey. There were no exclusion 
criteria. All questions were administered by a physician. The structured questionnaire included socio-de-
mographic data, drug use, and sexual behaviour history (Table S1 in Online Supplementary Document). 
Participants recruited in 2009 also agreed to answer a previously validated questionnaire about hepatitis 
B transmission and protection modes [6]. Consent forms and questionnaires were developed in nine lan-
guages (English, French, German, Italian, Spanish, Albanian, Russian, Chinese, and Greek). All data were 
anonymized. Parts of the survey were submitted three to five days after the blood test. During this period, 
seven participants were released and had therefore some missing data. Of note, there was no HBV-focused 
intervention between 2009 and 2011 that could have influenced the results. The Clinical Ethics Research 
Committee of the University Hospitals of Geneva (HUG) approved the study (EC: 09-137).
Laboratory and data analysis
Every participant underwent serological testing for HBV surface antigen (HBsAg), antibodies against HBV 
core antigen (anti-HBc) and antibodies against surface antigen (anti-HBs) (EIA Architect system, Unilabs 
laboratory, Geneva). HBsAg positivity signalled chronic infection. The presence of anti-HBc antibodies 
and negative HBsAg indicated resolved/prior infection. The presence of anti-HBs (>10UI/l) in the ab-
sence of HBsAg and anti-HBc indicated vaccine-acquired immunity, even if occult HBV infections could 
not be excluded. These cases are rare [10] and were not considered as a specific HBV status in our study.
Continuous variables were summarized as mean and standard deviation, and categorical variables as ab-
solute and relative frequencies. We calculated 95% confidence intervals of prevalence ratios [95% confi-
dence interval CI] using Wilson’s score interval. We also estimated how many people living in the canton 
of Geneva and having chronic HBV are susceptible to go through the correctional system. For this pur-
pose, we used data on the number of adults living in the canton of Geneva (381 000 adults aged more 
than 18 years), the number of people being incarcerated each year in Geneva (1789 adults), the preva-
lence rate of HBV in the Swiss population (0.18%), and the prevalence rate of HBV in the Champ-Dollon 
prison estimated in this study [11-13].
Differences between groups were then tested using the χ2 test. The Fisher exact test was used when the 
expected value in 2x2 contingency tables was less than 5. Association between HBV infection (chronic or 
resolved) and other categorical variables (age, gender, region of origin) was evaluated in bivariate anal-
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ysis. Participants with missing data were not included in the related analyses. Region of origin encom-
passed six regions of the world for participants’ home countries: Western Europe, Eastern Europe and the 
Balkans, North Africa, Sub-Saharan Africa, Latin America, and Asia. We stratified the study’s serological 
results based on known country-level HBsAg prevalence (HBV endemicity), using the WHO classifica-
tion and recent publications: “low” (<2.00%), “lower-intermediate” (2.00-4.99%), “higher-intermediate” 
(5.00-7.99%), and “high” (≥8.00%) (10-13). A logistic regression was performed to identify factors as-
sociated with HBV infection. All variables with p-value <0.20 in the bivariate analyses were included in 
a multivariate model. Since Champ-Dollon is a pre-trial prison with a high turnover of detainees, people 
incarcerated in 2009 were not the same as those incarcerated in 2011. All analyses were performed for 
the whole sample (2009 and 2011) and then separately for 2009 and 2011 to test whether there were sig-
nificant differences between the two time points. The statistically significant level was set to P < 0.05. All 
analyses were performed using SPSS for Windows (version 17.0) (IBM, Armonk, NY, USA) or OpenEpi 
(version 2.3.1) (open source software).
RESULTS
Socio-demographic characteristics and sexual health risks
Table 1 and Table 2 summarize the socio-demographic and sexual behaviour risks among the partici-
pants: out of 281 inmates, 273 agreed to participate in the study (116 in 2009, 157 in 2011, participa-
tion rate: 97.2%).
Table 1. Socio-demographic characteristics among inmates at the Champ Dollon prison in Geneva, Switzerland, 
2009 & 2011 (n = 273)
CharaCteristiCs total 2009 2011 P-value*
Sex (%, n):
Male 100 (273) 100 (116) 100 (157) –
Region of origin (%, n):
Central and Eastern Europe 38.1 (104) 36.2 (42) 39.5 (62) <0.001
Sub-saharan Africa 28.2 (77) 31.9 (37) 25.5 (40) <0.001
North Africa 14.3 (39) 21.6 (25) 8.9 (14) <0.001
Latin America 9.5 (26) 2.5 (3) 14.7 (23) <0.001
Western Europe 29.2 (5) 6.9 (8) 10.8 (17) <0.001
Asia 0.7 (2) 0.9 (1) 0.6 (1) <0.001
Age (mean years, SD) 29.8 (9.0) 27.7 (7.2) 30.9 (8.8) 0.002
Self-evaluated socioeconomic status (n, %):
Low 16.2 (43) 10.6 (12) 20.4 (31) 0.188
Moderate 77.4 (205) 83.2 (94) 73.0 (111) 0.188
High 6.4 (17) 6.2 (7) 6.6 (10) 0.188
Level of education (n, %):
No school 3.0 (8) 4.5 (5) 2.0 (3) 0.126
At least some primary school 14.0 (37) 15.9 (18) 12.5 (19) 0.126
Finished primary school 10.9 (29) 10.6 (12) 11.2 (17) 0.126
At least some secondary school 21.6 (57) 15.9 (18) 25.7 (39) 0.126
Finished secondary school 40.3 (107) 46.9 (53) 35.5 (54) 0.126
Some university education 10.2 (27) 6.2 (7) 13.1 (20) 0.126
Type of living area in childhood (n, %):†
Rural 19.8 (23) 19.8 (23) – –
Urban 80.2 (93) 80.2 (93) – –
Legal status (n, %):†
Undocumented 63.7 (76) 63.7 (76) – –
Non-European migrant with residence permit in Switzerland 22.1 (25) 22.1 (25) – –
Swiss or European passport 10.6 (12) 10.6 (12) – –
SD – standard deviation
*χ2 tests or Fisher exact tests for categorical outcomes and t tests for continuous outcomes.
†Only asked to 113 out of 116 participants in 2009.
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Two thirds of the participants (63.7%) were undocumented (no Swiss or European Union (EU) passport 
or residence permit in Switzerland) (Table 1), and 38.1% originated from Central and Eastern Europe, 
28.2% from sub-Saharan Africa, 14.3% from North Africa, 9.5% from America Latin, 9.1% from West-
ern Europe, and 0.7% from Asia. Mean age was 29.8 years (SD 9.0). Half of the participants (50.7%) 
had completed high school. In terms of sexual health, 2.3% reported to be homosexual and/or bisexual. 
More than half (53.0%) of the respondents reported having had sexual activities with sex workers and 
having experienced their first sexual encounter before the age of 16. Two-thirds (67.0%) reported occa-
sional or no condom use. The only significant differences between 2009 and 2011 were age (older partic-
ipants in 2011, P = 0.002), region of origin (in 2011, there were fewer participants from North Africa and 
more from Latin America, P < 0.001), and 
use of condom (more participants reported 
“sometimes” in 2009, P < 0.001).
Hepatitis B seroprevalence and 
region of origin
Figure 1 summarizes the HBV serologi-
cal profile of the study population: 5.9% 
(95%CI = 3.6-9.3) had a chronic infection 
(HBsAg+), 32.4% (95% CI = 32.7-44.1) 
had resolved HBV (anti-HBc+, but HB-
sAg-), and 14.0% (95% CI = 10.3-18.6) 
had a serological profile consistent with 
immunization (anti-HBc-, anti-HBs+). Just 
less than half of the inmates (47.7%, 95% 
CI = 41.9-53.7) had no detectable HBV 
markers, meaning that they were neither 
HBsAg carriers nor immune, and therefore 
susceptible to HBV infection. There was no 
significant difference between HBV status 
Table 2. Sexual health characteristics among inmates at the Champ-Dollon prison in Geneva, Switzerland,  
2009 & 2011 (n = 273)
CharaCteristiCs (%, n) total 2009 2011 P-value*
Sexual orientation:
Homosexual and/or bisexual 2.3 (6) 2.7 (3) 2.0 (3) .807
Heterosexual 97.7 (258) 97.3 (109) 98.0 (149) .807
Number of sexual partners over lifetime:
0 0.4 (1) 0.9 (1) 0 (0) .132
1 5.3 (14) 1.8 (2) 8.0 (12) .132
2 to 5 21.3 (56) 21.2 (24) 21.3 (32) .132
6 or more 73.0 (192) 76.1 (86) 70.7 (106) .132
Number of sexual partners in the 6 months before incarceration:
0 11.4 (30) 15.0 (17) 8.6 (13) .465
1 42.7 (113) 39.8 (45) 45.0 (68) .465
2 to 5 32.6 (86) 33.6 (38) 31.8 (48) .465
6 or more 13.3 (35) 11.6 (13) 14.6 (22) .465
Age of first sexual intercourse (years):
≤16 53.2 (133) 40.5 (45) 48.9 (68) .116
>16 46.8 (117) 59.5 (66) 51.1 (71) .116
Sexual intercourse with sex worker:
No 47.2 (125) 52.2 (59) 43.4 (66) .349
Yes 52.8 (140) 47.8 (54) 56.6 (86) .349
Use of condoms during sexual intercourse:
Always 33.0 (87) 21.4 (24) 41.4 (63) <.001
Sometimes 56.8 (150) 72.3 (81) 45.4 (69) <.001
Never 10.2 (27) 6.3 (7) 13.2 (20) <.001
*χ2 tests or Fisher exact tests.
Figure 1. Hepatitis B markers among inmates at Champ-Dollon prison in Geneva, 
Switzerland, 2009 and 2011 (n = 273).
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in 2009 and 2011 (P = 0.131 for the χ2 test). With a population of 381 000 adults in Geneva and a preva-
lence rate of 0.18% of HBV in the Swiss population, we can estimate that 686 persons per year are infected 
in the general population (381 000 × 0.0018). With 1789 adults incarcerated each year and a prevalence 
rate of 5.9% in Champ-Dollon prison, we can estimate that 106 persons are infected in the incarcerated 
population (1789 × 0.059). Therefore, 15.5% (106 out of 686 persons) of the infected persons go through 
Geneva’s prison for a given year.
In terms of anti-HBc positivity (ever infected with HBV), 72.2% (95%IC: 61.9-81.4) from sub-Saharan 
Africa were positive, 34.6% (95%CI = 26.2-44.2) from Central and Eastern Europe, and 13.2% (95% CI = 
7.7-21.6) from other regions (primarily Western Europe, Latin America, and North Africa) (P < 0.001) (Ta-
ble 3). The anti-HBc prevalence was statistically significant when aggregated by countries considered as 
“low” 9.1% (6/66), “lower-intermediate” 22.7% (17/75), “higher-intermediate” 46.3% (25/54), and “high” 
72.7% (56/77), (P < 0.001). Among the eastern European block, 49.0% of detainees from the “high-inter-
mediate” countries of Romania and Albania were positive for anti-HBc, compared to only 21.8% of those 
from the other Eastern European and Balkan countries (P = 0.004). Sub-Saharan African region was as-
sociated with presence of HbsAg (chronic HBV infection) with a prevalence of 15.6% vs 2% participants 
from other regions, all combined (P < 0.001). HBsAg endemicity per country also followed a statistically 
significant difference (P = 0.001): “low to lower-intermediate countries” 1.4% (2/141), vs “higher-inter-
mediate to high countries” 10.7% (14/131).
Table 3. Association between positive HBV surface antigen (HBsAg), positive core antibody (AntiHBc) and sociode-
mographic and sexual health characteristics among inmates at the Champ-Dollon prison in Geneva, Switzerland, 
2009 & 2011 (n = 273)
n hBsag+/total (%) P-value antihBC+/total (%)* P-value
Region of origin:
Sub-Saharan Africa 77 12 (15.6%) <0.001† 56 (72.7%) <0.001
Other regions 196 4 (2.0%) 48 (24.6%)*
Age (years):
≥28 141 7 (5.0%) 0.51 54 (38.6%)* 0.91
<28 132 9 (6.8%) 50 (37.9%)
Education level:
Secondary school 191 8 (4.2%) 0.56† 70 (40.9%)* 0.72
Never to secondary school 74 5 (6.8%) 29 (39.2%)
Condom use for sexual protection:
Sometimes or never 177 9 (5.1%) 0.73† 70 (39.5%)* 0.41
Always use condoms 87 6 (6.9%) 30 (34.5%) 0.41
Man who has had sex with men:
Yes 6 1 (16.7%) 0.60† 4 (66.7%) 0.30†
No 258 14 (5.4%) 96 (37.2%)*
Number of sexual partners (lifetime):
6 or more 192 8 (4.2%) 0.29 70 (36.5%)* 0.84
0 to 5 71 6 (8.5%) 27 (38.0%)
Number of sexual partners (6 months before incarceration):
6 or more 35 2 (5.7%) 0.99† 9 (25.7%) 0.12
0 to 5 229 13 (5.7%) 90 (39.3%)*
Age of first sexual intercourse (years):
≤16 133 6 (4.5%) 0.60 53 (39.8%) 0.25
>16 117 7 (6.0%) 38 (32.7%)*
Sexual intercourse with sex workers:
Never 125 9 (7.2%) 0.31 44 (35.2%) 0.39
At least once 140 6 (4.3%) 56 (40.3%)*
Injection drug use:
Yes 16 0 (0%) 0.78† 7 (43.8%) 0.65
No 253 15 (5.9%) 96 (38.0%)*
Type of living area:‡
Rural 23 0 (0%) 0.65† 14 (60.9%) 0.07
Urban 93 5 (5.4%) 37 (39.8%)
*Not enough serum for antiHbc for one participant.
†Fischer exact test.
‡Only asked to 113 out of 116 participants in 2009.
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Hepatitis B seroprevalence and other factors
In bivariate analysis (Table 3), the results showed no association between HBV infection (chronic or re-
solved) and age, education level, number of sexual partners, age of first sexual activity, history of sexual 
activity with sex workers, same-sex sexual activities, injection drug use, rural or urban living, or “non-use” 
of condoms. In further sensitivity tests including all factors with P-values <0.20 (multivariate regression 
checks) only region of origin was significantly associated with presence of anti-HBc. Disaggregated anal-
yses for 2009 and 2011 yielded similar results (not shown in Table 3).
Knowledge about infection and vaccination history
Out of the 16 patients with chronic hepatitis B, 2 (12.5%) knew about their status. The first 116 partici-
pants who joined the study also answered questions about vaccination history: 15.0% were certain about 
prior vaccination, of whom 35.3% (5.3% of all participants) reported reception of 3 doses. Eight had an-
ti-HBs suggestive of vaccination, 7 had resolved HBV (anti-HBc without HBsAg) and 2 were susceptible 
to HBV. Among the 30 detainees who reported no vaccination, 46.7% were immune post hepatitis B in-
fection (anti-HBc+), but 10.0% had chronic hepatitis B (HBsAg+).
Knowledge about transmission of and protection against HBV
Among the first 116 participants included in the study in 2009, 113 answered a questionnaire assessing 
their knowledge of and protection against HBV transmission (Table 4). Only 27% of participants knew 
that HBV could be transmitted by syringe exchange, 21% by razors or toothbrushes exchange, and 19% 
through tattoos. Overall 21% and 27% stated that using condoms and sterile syringes, respectively, could 
prevent HBV infection.
Table 4. Knowledge about hepatitis B transmission and prevention modes among inmates at the Champ-Dollon 
prison in Geneva, Switzerland, 2009 (n = 113)
Questions % (n)
Can you get hepatitis B from having unprotected sex?
Yes 24.8 (28)
No or I don’t know 75.2 (85)
Can you get hepatitis B from sharing needles?
Yes 26.6 (30)
No or I don’t know 73.4 (83)
Can you get hepatitis B from sharing toothbrushes or razors?
Yes 21.2 (24)
No or I don’t know 78.8 (89)
Can one get hepatitis B by eating contaminated food?
No 9.7 (10)
Yes or I don’t know 90.3 (103)
Can you get hepatitis B from being tattooed?
Yes 19.5 (22)
No or I don’t know 80.5 (91)
Can a baby be infected with hepatitis B at birth, when born to a hepatitis B positive mother?
Yes 15.9 (18)
No or I don’t know 84.1 (95)
Can drinking alcohol make liver disease worse if you have hepatitis B?
Yes 15.0 (17)
No or I don’t know 85.0 (96)
Can one avoid hepatitis B infection by using condoms during sexual intercourse?
Yes 21.2 (24)
No or I don’t know 78.8 (89)
Can one avoid hepatitis B infection by using sterile needles?
Yes 27.4 (31)
No or I don’t know 72.6 (82)
Hepatitis B among prison inmates in Switzerland
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DISCUSSION
Hepatitis B seroprevalence
With regard to chronic hepatitis B, 5.9% of the surveyed population in Champ-Dollon were HBsAg car-
riers, which is 33 times higher than the proportion in the general Swiss population [14]. This prevalence 
ranks among the highest values recorded in prisons in Europe and in the United States [4,5,15]. Addi-
tionally, a simple estimation suggested that 15.5% of HBV infected people living in the Canton of Geneva 
go through the correctional system each year. Because these persons are among the most hard-to-reach 
in the community, the detention system has a civil responsibility facing the challenge of controlling these 
diseases. This is also a unique opportunity to treat this disease and protect other people of being infecting.
HBV infection and associated risk factors.
The differences in HBV seroprevalence by region of origin found in the study are similar to the differences 
found in the literature, even by pre-determined stratification classes. Countries in sub-Saharan Africa are 
characterized by high percentages of HBsAg positivity (greater than 8%), which is reflected by the high 
prevalence found among migrants from these countries in Europe [16]. North African countries are clas-
sified at the “low” or “lower-intermediate” levels. In Western European countries, the prevalence is low. 
The epidemiology of hepatitis B in Eastern Europe (including Balkan countries) is more heterogeneous: 
Serbia, Croatia, Bosnia and Herzegovina, and Slovenia report low prevalence, while Albania and Roma-
nia have “high-intermediate” HBV endemicity [14,16-19]. About half (48%) of the study population and 
88% of chronic hepatitis B cases came from countries with “higher-intermediate” (Albania, Romania) or 
“high” (sub-Saharan Africa) endemicity levels of HBsAg. These concordant findings show that prevalence 
figures among the general population in the country of origin can be extrapolated to prison populations 
in order to estimate risk of HBV by region of origin.
Sexual health risk factors (number of sexual partners, reported age of first sexual intercourse, history of 
activity with sex workers, and “non-use” of condoms) were not significantly related to infection in our 
study. These factors are known to be associated with HBV transmission [20-22]. It is possible that the 
sensitive nature of these questions led to an under-reporting of these sexual behaviours by prisoners. 
This however underscores that in prison populations, asking these sensitive questions may not always 
be useful in selecting subpopulations that are most at risk for HBV, given that many patients will not an-
swer the question accurately.
This study did not show a statistically significant correlation between low education and chronic hepa-
titis B, contrariwise to previous studies, which demonstrated a clear link between low education status 
and HBV infection [20,23,24].
The relationship between age and hepatitis B is less clear in the literature: among some prisons in Europe, 
Australia and the United States, markers of HBV infection are higher in older age groups [25-27]. Howev-
er, among prisons in sub-Saharan Africa (Nigeria, Ghana), younger age is associated with HBV infection 
[28,29]. We did not find evidence for this association in our sample. Further data are needed on this topic.
HBV infection and knowledge about HBV status
Knowledge of having been infected by HBV among seropositive inmates was very low. Among 16 inmates 
with chronic HBV infection, only 2 (12.5%) knew that they were infected, which corresponds to values 
reported in the general Swiss population [30]. A previous study of medical files in this population (no 
systematic serological screening) showed a 1% prevalence of self-reported chronic HBV [31]. This under-
estimate corroborates that the majority of people living with chronic HBV infection in this population are 
unaware of (or ignore) their status- thus re-affirming the necessity for active HBV surveillance in prison. 
Furthermore, among the inmates reporting prior vaccination, 29% had antibody levels that would not 
ensure long-term protection (anti-HBs <100); 12% were HBV susceptible, and 41% possessed markers 
of past/resolved HBV infection. These results suggest that in the absence of serological markers, a verbal 
history about vaccination and immunity is not reliable in this population.
Implications for HBV screening, vaccination strategies, and education
HBV serological screening has two objectives: 1) to diagnose chronic HBV infection, and 2) to detect peo-
ple who are not appropriately immunized and need vaccination. Studies that incorporate cost-effective-
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ness measures recommend routine screening for chronic HBV (HBsAg positive) when the pre-test prob-
ability in the population is higher than 2% and when access to treatment for the majority of diagnosed 
patients is ensured (58-100% depending on the models) [32-34]. Access and adherence to the long anti-
viral treatment is challenging in the prison setting due to poor continuity of care and follow up, and risks 
of breakthrough resistance secondary to lapses in treatment [35]. Despite issues with treatment initiation, 
screening for HBV remains beneficial in the prison setting, as those diagnosed by routine screening could 
benefit from health education in order to 1) limit the risk of a downward evolution of the disease (for ex-
ample, only 15% of our participants knew that alcohol consumption could worsen liver damage in the 
presence of HBV infection), and 2) modify unsafe behaviours that could increase the risk of further HBV 
transmission in prison and after release [36].
Given the prevalence of HBV in our study population, HBV prevention and control measures should be 
offered to inmates during their time in prison. This could benefit their health and also protect the com-
munity as a whole. For instance, Pisu, Meltzer, & Lyerla [37] demonstrated that the health care system 
benefits from allocating resources for prison HBV vaccination programs, and the United States Center for 
Disease Control recommends routine HBV immunization, chronic HBV screening, and HBV preventive 
health education while in prison [3].
Because HBV infection and the region of origin are significantly associated in this population, it could be 
proposed that patients from “high-intermediate” and “high” level HBV countries (who actually make up 
about half of the prison population: Albania, Georgia, Bulgaria, and countries in Sub-Saharan Africa), re-
ceive systematic screening for resolved and chronic HBV (anti-HBc and HBsAg). Non-immune individ-
uals should receive immunization, while chronic HBV patients would benefit from intensive educational 
and therapeutic programs. Those from countries with “low” or “lower-intermediate” HBV levels would 
be vaccinated without testing.
An American study in 2002 using a similar questionnaire showed that 75% of their prison participants 
were aware of the primary modes of HBV transmission (considered less than ideal) [6]. Our results in-
dicate an even lower level of HBV knowledge, thus reinforcing the potential impact of educational pro-
grams. Weinbaum et al. [3] have demonstrated that educational programs that target HBV prevention in 
prison are effective.
Finally, stigmatization acts as a barrier for prevention and treatment. Indeed, it often prevents people from 
seeking screening and treatment. Stigmatization is largely due to ignorance about the disease. Therefore, 
the prison environment is a unique opportunity to propose adequate education, prevention, and treat-
ment for people at risk of being infected [38]. Since migrants are likely to be discriminated against, efforts 
should be made to avoid further stigmatization due to this infectious disease.
Limitations and strengths
A limitation in this project is the convenience sample of the study. Nevertheless, this sample was repre-
sentative of the prison population; recruitment bias was minor with a high participation rate (97%), and 
no policy of attribution of cells according to the origin of the prisoners (or any other criterion) existed. 
The study population represented respectively one-fifth and one-third of all prisoners incarcerated at 
the time of recruitment in 2009 and 2011. Because participants were asked to answer questions about 
themselves in terms of education (self-assessment) and sexual health (taboo questions), this informa-
tion may have been less reliable due to reporting bias and social desirability, given that the questionnaire 
was completed face-to-face with a physician. Among participants with a serological pattern compatible 
with a resolved HBV (anti-Hbc pos/HbsAg neg), occult HBV infections were not excluded. Since these 
cases are rare, under-evaluation of chronic HBV prevalence in the study population would be very lim-
ited [10]. Future studies could focus on occult HBV infection among inmates. It would give an idea of 
the number of these cases, even if it concerns a very small proportion of active HBV cases. In this pop-
ulation, data about vaccination was confusing and participants did not reliably report their vaccination 
history. In terms of study strengths, we highlight the participation rate of 97%; these results are useful in 
the implementation of hepatitis B preventive measures in a population that lacks epidemiological data. It 
must be noted that this study population was entirely male and focused on a single prison in Switzerland. 
However, the study population is similar to that of other pre-trial Swiss prisons, which are also charac-
terized by a high proportion of immigrants (81.4%) and men (94%) [39]. Therefore, these results are of 
importance to prison health providers in Switzerland, and also in all countries where the proportion of 
migrants in prison is high. In Europe, immigrants represent a high proportion of the correctional popu-
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lation. In 2012, foreigners accounted for 21% of the estimated 1.73 million people detained in the pris-
ons of the 47 Member States of the Council of Europe. The vast majority of foreign detainees originated 
from low-income countries [40]. Therefore, an inclusive approach to global health needs to incorporate 
prison population, as incarcerated people have a disproportionate burden of HBV infection [41]. In ad-
dition to the risk of transmission in custody between inmates and to the staff, on release there is the risk 
of HBV being transmitted to the wider community, as infected inmates represent a risk for their partners 
at the return to freedom. Our results recall that origin must also be taken into account within the com-
munity among migrant populations native from HBV endemic countries.
CONCLUSIONS
The prevalence of chronic HBV infection was 5.9% at the Champ-Dollon prison, 33 times higher than 
the general Swiss population [14]. The main risk factor for infection was region of origin. Other known 
socio-demographic risk factors for HBV were not reliable in our prison setting, thus limiting their use in 
risk-stratifying patients for hepatitis B. A targeted testing and vaccination approach based on the prison-
er’s region of origin is a potential control strategy, especially because an important proportion of the in-
fected and hard-to-reach population go through the detention system. Patient information, education, 
and counselling on HBV transmission modes should be offered to all inmates. An inclusive approach to 
global health needs to incorporate prison population, as incarcerated people have a disproportionate bur-
den of HBV infection.
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